New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:06 EDTBDSI, ENDPEndo, BioDelivery Sciences announces positive results from buprenorphine trial
Endo Pharmaceuticals, a subsidiary of Endo International (ENDP) and BioDelivery Sciences (BDSI) announced positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. The trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to placebo. Additional secondary endpoints were supportive of the efficacy of BEMA buprenorphine compared to placebo. The most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea and vomiting.
News For ENDP;BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
07:03 EDTENDPEndo price target raised to $110 from $102 at Piper Jaffray
Subscribe for More Information
April 8, 2015
10:01 EDTBDSIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
April 7, 2015
19:10 EDTBDSIOn The Fly: After Hours Movers
Subscribe for More Information
16:10 EDTBDSIBioDelivery Sciences initiated with a Buy at Cantor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use